Clinical Trials & Research

A promising study shows that a combination of two monoclonal antibodies effectively neutralized the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in monkeys and proved efficacious against newer variants of concern in vitro. This could help develop preventive pharmacological measures against the spread of the virus to susceptible contacts. Study: A combination of two human
0 Comments
The Family Health Centers at NYU Langone in Sunset Park, Brooklyn, has been awarded a $24 million federal grant through the American Rescue Plan Act of 2021 to advance COVID-19 vaccination and education and expand access to high-quality comprehensive care in some of New York City’s lowest-income neighborhoods. The 2-year grant is part of a
0 Comments
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants. The awards are intended to fuel vaccine research for a diverse family of coronaviruses,
0 Comments
A 2013 study by Pérez et al. reported a very high accumulation of the industrial chemical perfluorobutanoic acid (PFBA) in human lungs and kidneys. The German Federal Institute for Risk Assessment (BfR) checked these results using a more precise quantification method. The result: Only one sample contained a quantifiable PFBA value of 0.17 nanograms (ng)
0 Comments
Developing the advanced and powerful detection techniques to characterize as many endocrine disruptors as possible with ultra-sensitivity in the environment is still challenging, however highly demanded. Environmental estrogens (EEs), as typical endocrine disruptors, have been listed as one of the global environmental issues to be addressed through international collaboration by the United Nations. They are
0 Comments
This landmark study aims to improve the treatment of patients receiving end-of-life care and lead to a more uniform approach and consistent management within the NHS. The trial will assess the overall effectiveness and cost-effectiveness ofclinically-assistedhydration in reducing the frequency of delirium and its effect on the frequency of pain and other symptoms such as
0 Comments
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has mutated since its initial emergence in Wuhan, China, in late 2019. to survive. A select few mutations have allowed the virus to spread faster and cause more severe infection. Variants of concern that contain such mutations, such as the Delta variant, have also acquired mutations to
0 Comments
Scientists from the USA have recently compared the dynamics of humoral and cellular immune responses induced by mRNA-based and adenoviral vector-based coronavirus disease 2019 (COVID-19) vaccines. The findings reveal a difference in humoral immune responses. The study is currently available on the medRxiv* preprint server. Background In the USA, three COVID-19 vaccines have been approved
0 Comments
Coronavirus disease 2019 (COVID-19) disproportionately affects patients 65 years and older. Age-related impaired host immunity has been implicated for severe outcomes of COVID-19. Researchers have performed a study on large data set to understand better the molecular basis of vulnerability in aged COVID-19 patients. They observed certain age-linked immunoinflammatory factors associated with severe COVID-19 and
0 Comments
A distinguishing feature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to severe acute respiratory syndrome (SARS) is that it is spread not only via symptomatic people but also asymptomatic and pre-symptomatic people. Asymptomatic cases are becoming of increasing concern due to the potential of people unknowingly causing local outbreaks within their communities. In
0 Comments
Scientists have recently tried to explain the factors that could be responsible for the recent outbreaks of coronavirus disease 2019 (COVID-19) in Israel. Their observations reveal that the prevalence of the more infectious delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and waning vaccine efficacy results in the outbreaks. As preventive interventions, they
0 Comments
Researchers worldwide hypothesized that the development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help to reduce transmission and help to lower the mortality rate. The vaccines developed against coronavirus disease 2019 (COVID-19) had to undergo several clinical trials before they could be considered safe for human use. Patients of various age
0 Comments
The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused an economic and healthcare crisis. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-stranded and RNA virus belonging to the family Coronaviridae. This virus is highly virulent and has already claimed more than 4.66 million live worldwide. Study: Neutralizing Monoclonal Antibodies
0 Comments
In a report currently available on the bioRxiv* preprint server, scientists from the USA have demonstrated that immunity induced by mRNA-based coronavirus disease 2019 (COVID-19) vaccines in previously severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected people has the highest robustness and durability with cross-reactivity against different viral variants. Study: Differential antibody dynamics to SARS-CoV-2 infection
0 Comments
Immunocompromised patients benefit from receiving the two-dose Pfizer-BioNTech vaccine, according to a new study available on the preprint server medRxiv*. The clinical trial showed that about 72.2% of immunocompromised patients had detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While the vaccine was safe and effective, immunocompromised patients developed fewer antibodies than patients
0 Comments
Recent data indicates that individuals are experiencing coronavirus disease 2019 (COVID-19) symptoms long after clearing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which suggests the virus has profound consequences to host cells. Study: SARS-CoV-2 triggers DNA damage response in Vero E6 cells. Image Credit: Festa/ Shutterstock RNA viruses, such as SAR-CoV-2, are renowned for
0 Comments
A new study by the ICTA-UAB establishes that the population density of hunter-gatherer groups was reduced where they depended heavily on meat to survive. Hunter-gatherer populations with a strong seasonal dependence on meat in their diets had fewer people per square kilometer than those that had abundant plant foods throughout the year. This new result
0 Comments
Sandrine V. Pierre, Ph.D., associate professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine and interim director of the Marshall Institute for Interdisciplinary Research (MIIR), has been awarded a Research Project Grant (R01), one of the most competitive grants issued by the National Institutes of Health (NIH). Pierre was awarded
0 Comments
A team of international scientists has recently assessed the strategies adopted by the Nordic countries to curb the trajectory of the coronavirus disease 2019 (COVID-19) pandemic. Their findings reveal that to decrease the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is important to minimize the number, size, and duration of transmission clusters
0 Comments
GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax’ seasonal influenza and COVID-19 vaccines. The
0 Comments
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus that causes coronavirus disease 2019 (COVID-19) – is not associated with neuroaxonal damage, according to a new study from researchers in Germany. Neurological symptoms have been observed in about one-third of coronavirus cases. However, the full extent of the virus’s impact on the brain
0 Comments
LA ROCHELLE, France. Sept 6, 2021 – Valbiotis, a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has completed the recruitment of 120 volunteers for the Phase II HEART clinical study at the beginning of September 2021, in accordance with the schedule announced by the
0 Comments
Since it was first detected in December 2019 in Wuhan, China, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus that causes coronavirus disease 2019 (COVID-19) – has infected over 217 million people worldwide. To date, this has led to over 4.56 million deaths worldwide. The COVID-19 pandemic continues to affect more
0 Comments
SAN FRANCISCO, Sept. 3, 2021.  Quantum Leap Healthcare Collaborative, the sponsor of the I-SPY COVID Trial, today announced that the Famotidine Celecoxib arm has been dropped from the trial due to futility, based on the low likelihood of success. The Famotidine Celecoxib combination was chosen for testing because of their anti-histamine and anti-inflammatory mechanism of
0 Comments